Yisi D. Ji

Everolimus-associated stomatitis in a patient who had renal transplant

Everolimus is used as an immunosuppressant in renal allograft transplant rejection and in metastatic breast cancer treatment. One side effect of everolimus is stomatitis, referred to as mammalian target of rapamycin inhibitor-associated stomatitis. This side effect can affect treatment course and contribute to discontinuation of therapy or dose reduction, previously reported in the treatment of metastatic breast cancer. Here, we present a case of everolimus-associated stomatitis with a novel management method with intralesional triamcinolone that allows for continuous course of everolimus.

WITHDRAWN: Health Policy Research May Ensure the Future of Oral and Maxillofacial Surgery

The Publisher regrets that this article is an accidental duplication of an article that has already been published, https://doi.org/10.1016/j.joms.2017.03.056. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.